IL10 and lymphopenia: In a humanized NSG mice model, treatment with the CAR-Treg led to increased levels of IL-10, decreased positivity of anti-dsDNA, delayed the onset of lymphopenia and decreased inflammation in lung, spleen and kidney biopsies.